Cencora, Inc. (COR)
Cencora, Inc. (COR) from its SEC filings: 2025 revenue $321.3 billion (+9% vs the year before), net margin 0%, free cash flow $3.2 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Wholesale-Drugs, Proprietaries & Druggists' Sundries |
| Revenue (2025) | $321.3 billion |
| Revenue growth | +9% |
| Net income | $1.6 billion |
| Net margin | 0.5% |
| Free cash flow | $3.2 billion |
| Diluted EPS | $7.96 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +5% |
| Cash | $2.8 billion |
| Long-term debt | $11.4 billion |
| Share count, 1 year | -2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.